Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::NTRK3 status confers therapeutic sensitivity to Larotrectinib in patients with Any solid tumor.
This statement is based on a regulatory approval from the Health Service Executive:
For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have no satisfactory treatment options